Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

With UAB and Southern Research, many have assumed that Birmingham is the state’s life sciences giant, but that thinking may ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic and Paralympic Winter Games, the company is drawing parallels between what ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...